过去一年中添加的文章，按日期排序
A novel CCR4 antagonist induces potent anti-tumor response through inhibition of Treg migration into the tumor microenvironment
R Nair, C Abbineni, KC Talluri, AA Dhudashiya, A AB… - Cancer Research, 2024 - AACR
100 天前 - … CCR4 expression is associated with poor prognosis in various solid tumors. This …
the therapeutic targeting of CCR4-expressing Tregs to enable effective and durable anti-tumor …
the therapeutic targeting of CCR4-expressing Tregs to enable effective and durable anti-tumor …
[引用][C] Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4
M Wang - Precision Cancer Therapies vol 2‐Immunologic …, 2024 - Wiley Online Library
131 天前 - … or solid cancers. This discovery of onco-embryonic expression soon attracted
research attention directed toward therapeutic targeting in patients with ROR1-expressing cancer. …
research attention directed toward therapeutic targeting in patients with ROR1-expressing cancer. …
METTL3 promotes cellular senescence of colorectal cancer via modulation of CDKN2B transcription and mRNA stability
Z Chen, J Zhou, Y Wu, F Chen, J Li, L Tao, Y Tian… - Oncogene, 2024 - nature.com
136 天前 - … recruiting IGF2BP3 and preventing binding with the CCR4-NOT complex. Moreover,
increased … provides a new potential therapeutic target for CRC treatment and expands our …
increased … provides a new potential therapeutic target for CRC treatment and expands our …
[图书][B] Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice
OA O'Connor, SM Ansell, JG Gribben - 2024 - books.google.com
151 天前 - … an array of therapeutic targets and modalities coupled with vital insights to …
Cancer immunotherapy, the science of mobilizing the immune system to treat cancer, has been …
Cancer immunotherapy, the science of mobilizing the immune system to treat cancer, has been …
Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer
AS Franzén, A Boulifa, C Radecke, S Stintzing… - Cancers, 2024 - mdpi.com
166 天前 - … High CCR4 expression in colorectal cancer tissues has been associated with shorter
… marker for targeted therapies. Our findings validate that the incorporated CCR4 element …
… marker for targeted therapies. Our findings validate that the incorporated CCR4 element …
Abstract LB_C20: A tumor-associated chemokine attracts CCR4-expressing CD4+ cells to foster immune repression and tumor aggressiveness in MYCN-driven …
X Qin, A Lam, X Zhang, S Sengupta… - … Cancer Therapeutics, 2023 - AACR
212 天前 - … TME while promoting rapid tumor onset and progression. We also … , tumor cells
secrete TAC to attract CCR4-expressing Cd4 + cells to induce immunosuppression and tumor …
secrete TAC to attract CCR4-expressing Cd4 + cells to induce immunosuppression and tumor …
The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas
A Dupuy, L Pelletier, J Giustiniani, P Kim, K Bisht… - Blood, 2023 - Elsevier
216 天前 - … improved the prognosis of many cancers. However, so far, only two antibodies
targeting CCR4 and CD30 have been approved for the treatment of subsets of PTCL patients. …
targeting CCR4 and CD30 have been approved for the treatment of subsets of PTCL patients. …
Mogamulizumab for Refractory CD3-CD4+ Lymphocytic-Variant Hypereosinophilic Syndrome
E Ledoult, M Groh, B Meresse, R Dubois, J Trauet… - Blood, 2023 - Elsevier
216 天前 - … cells express CC chemokine receptor 4 (CCR4). We hypothesized that mogamulizumab,
an afucosylated monoclonal antibody targeting CCR4-positive cells through antibody-…
an afucosylated monoclonal antibody targeting CCR4-positive cells through antibody-…
… and Effector Differentiation Following Subcutaneous (SC) Mosunetuzumab Administration in Patients with Untreated, High Tumor-Burden Follicular Lymphoma (FL)
216 天前 - Introduction: Bispecific antibodies (BsAb) have emerged as a potent therapeutic
option for patients with B-cell non-Hodgkin lymphoma, including FL. These drugs leverage …
option for patients with B-cell non-Hodgkin lymphoma, including FL. These drugs leverage …
North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351
216 天前 - … These mutations result in a more stabilized surface CCR4 and have been …
targeted exon sequencing study did not include CCR4, this work was initiated to assess CCR4 …
targeted exon sequencing study did not include CCR4, this work was initiated to assess CCR4 …